Last updated: March 18th, 2026
Herspiegel’s Most Favored Nation (MFN) Exposure Assessment Tool helps manufacturers evaluate whether a product may be exposed to MFN pricing pressure or related enforcement mechanisms.
As global pricing policies evolve and reference pricing frameworks expand, manufacturers increasingly need to understand when, where, and under what conditions MFN exposure may affect their pricing and access strategies.
In just a few minutes, this assessment provides a high-level exposure screening based on your product profile, helping teams identify potential areas that may require closer strategic review.
What Is the MFN Exposure Assessment Tool?
The MFN Exposure Assessment Tool is a self-guided strategic screening tool designed to help manufacturers quickly evaluate potential MFN-related pricing exposure.
By answering a short series of structured questions about your therapeutic category, reimbursement pathway, Medicare spend, Medicaid status, and MFN participation considerations, the tool provides a directional assessment of potential exposure. The results help identify whether MFN policies may apply, where exposure may emerge, and which conditions may warrant further review.
The tool helps translate complex policy considerations into clear, actionable insights for pricing and market access strategy.
Why Use the MFN Exposure Assessment?
The MFN Exposure Assessment Tool helps manufacturers:
Evaluate whether MFN policies may currently apply to a product
Identify where potential pricing exposure may emerge across markets or reimbursement frameworks
Recognize thresholds or triggers that may warrant closer review
Support earlier pricing and access strategy discussions
Rather than reacting once pricing pressure emerges, the assessment helps teams identify potential risks earlier and plan more strategically.
What You Will Receive
After completing the assessment, you will receive a high-level exposure readout summarizing key considerations across several areas:
Implications: What the assessment signals about potential MFN-related exposure
Strategic Priority: Where MFN considerations may warrant greater strategic focus
Exclusion Criteria: Whether certain policy exclusions may apply to the product
Practical Implications: Next steps for pricing and market access strategy
The results provide an early directional view of potential MFN exposure, supporting more detailed evaluation of scenarios, underlying assumptions, and strategic priorities.
If you would like to go deeper, our team would welcome the opportunity to discuss what the results may mean for your product.
Who Should Use This Tool?
This assessment is most valuable for Market Access, Pricing, and Global Value teams evaluating implications across Medicare Part B, Part D, Medicaid, and global reference pricing.
Start the MFN Exposure Assessment
Identify whether MFN-related pricing exposure may affect your product and gain an early view of potential strategic considerations.
Start the Assessment →
Request a Consultation
Meet the Experts:
FAQs for MFN Exposure Assessment
1. What is the MFN Exposure Assessment Tool?
A self-guided assessment that helps evaluate whether a product may be exposed to MFN-related pricing pressure.
2. Who should use this tool?
Professionals involved in pricing, market access, and commercial strategy within pharmaceutical and biotech organizations.
3. How long does the assessment take?
The assessment typically takes approximately 3–5 minutes to complete.
4. What does the tool evaluate?
The assessment reviews key product and policy factors to indicate where MFN policies may apply and where exposure may emerge.
5. What happens after I complete the assessment?
You will receive an exposure assessment that can help guide internal pricing and access strategy discussions.
© 2026. Herspiegel.